Table 2.
T0 pre-NP | T0 post-NP | T0 pre-HP | T0 post-HP | T8 pre-NP | T8 post-NP | T8 pre-HP | T8 post-HP | |
---|---|---|---|---|---|---|---|---|
IL-6 | <2.000 | <2.000 | <2.00 | <2.00 | <2.00 | <2.00 | <2.00 | <2.00 |
IL-1β | <1.50 | <1.50 | <1.50 | <1.50 | <1.50 | <1.50 | <1.50 | <1.50 |
TNF-α | 5.9±0.46 | 7.12±0.88 | 6.44±0.65 | 7.78±0.59 | 15.79±7.4 | 11.34±1.57 | 11.04±2.16 | 10.53±1.06 |
MSTN | 1.79±0.86 | 5.36±0.58 | 7.29±3.15 | 3.87±1.46 | 4.23±2.55 | 3.64±2.09 | 3.65±1.43 | 12±2.50* |
IGF-1 | 229.4±20.84 | 223.6±22.30 | 226.9±9.04 | 231.2±12.35 | 216.2±17.31 | 220.4±17.58 | 221.6±14.28 | 222.0±15.04 |
Data are expressed as mean and standard error of mean. Data were analyzed through two-way ANOVA repeated measurements (time×treatment). A Bonferroni multiple comparison showed significance for T8 post.
P=.02 (HP T8 post vs. NP T8 post).
IGF-1, insulin-like growth factor 1 (expressed in ng/mL); IL-1β, interleukin 1 beta (expressed in ng/L); IL-6, interleukin 6 (expressed in ng/L); MSTN, myostatin (expressed in ng/mL); TNF-α, tumor necrosis factor alpha (expressed in ng/L).